Buprenorphine in Neonatal Abstinence Syndrome.
Publication/Presentation Date
1-1-2018
Abstract
Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and treatment cohorts demonstrate the efficacy and safety of sublingual buprenorphine for those infants with NAS who require pharmacologic treatment. Pharmacometric modeling will assist in defining the exposure-response relationships and facilitate dose optimization.
Volume
103
Issue
1
First Page
112
Last Page
119
ISSN
1532-6535
Published In/Presented At
Kraft W. K. (2018). Buprenorphine in Neonatal Abstinence Syndrome. Clinical pharmacology and therapeutics, 103(1), 112–119. https://doi.org/10.1002/cpt.930
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
29105752
Department(s)
Administration and Leadership
Document Type
Article